|
||
|
|
|
||
|
|
In terms of bleeding outcomes, the Figure shows that all except gastrointestinal bleeds were significantly reduced with apixaban versus warfarin. Intracranial bleeding, in particular, was reduced by almost 60%. In contrast to the other approved factor Xa inhibitor, however, GI bleeding was not increased, highlighting that there are subtle differences among the agents.
Reiffel JA. Am J Med 2013; 126: 00-00.
[99] Granger CB, Alexander JH, McMurray JV, et al; the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.